Ticker

Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF, a large underserved market. TX45's engineered Fc-relaxin fusion overcomes prior failures by extending half-life, enabling durable hemodynamic improvements in the CpcPH subgroup per robust phase 1b data. With a $253.8M cash balance, TECX is funded for phase 2; positive topline data in 2026 could unlock a…

Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating

Aberdeen Group plc boosted its holdings in shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) by 220.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,141,824 shares of the company's stock after acquiring an additional 785,648 shares during

Ally Bridge Group NY LLC lowered its stake in shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) by 15.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 138,595 shares of the company's stock after selling 25,088 shares during the quarter. Tectonic Therapeutic accounts

Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on